

Dr. rer. nat. Kamal Al-Shami



Postdoc - DKFZ, Heidelberg

Role in LiSyM-Cancer

- SMART-NAFLD
- Schulze Lab

Expertise

- Biochemistry
- Lipidomics
- Molecular Biology
- Liver metabolism
- Metabolism
- Wet lab
- Cell cultivation
- Tumor biology
- Animal models

Professional Experience

Postdoctoral Researcher with PhD-training in molecular biologist and clinical pharmacist with eight years of experience in cancer metabolism, molecular oncology, advanced biomolecular and preclinical techniques.

Degrees

- **PhD (Dr. rer. nat.)**
Heidelberg University
Defining oncogene-specific metabolic alterations in a mouse model of hepatocellular carcinoma for therapeutic targeting
 - Fellowship in Responsible Conduct of Research (RCR), UCSD and JUST, Jordan & USA
- **Master of Science: Clinical Pharmacy**
Jordan University of Science and Technology
Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
- **Bachelor of Science: Pharmacy**
Jordan University of Science and Technology

Honors and Awards

- Scholar-in-training Award, American Association for Cancer Research (AACR) 2024, USA
- Graduate School Scholarship Program, German academic exchange service (DAAD), Germany
- In-Country/In-Region scholarship, German Academic Exchange Service (DAAD), Germany

Publications

2025-02-01 Targeting aldolase A in hepatocellular carcinoma leads to imbalanced
glycolysis and energy stress due to uncontrolled FBP accumulation
Nature Metabolism
